We receive funding from a variety of sources that recognize the value of our high-impact research.
Brahm Segal, MD
Novel Immunological Biomarkers in Ovarian Cancer Prognosis. Brahm Segal (Principal Investigator). NIH. $3,148,229. 6/1/2015-5/1/2023.
Targeting complement to enhance antitumor immunity and control malignant effusions in patients with recurrent epithelial ovarian cancer. Brahm Segal (Principal Investigator). NCI. $3,310,823. 8/1/2022-8/1/2027.